 Approximately 184 persons with ICH will be enrolled in one of two study groups at 10 clinical sites across the United States and Canada. Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth CTA spot sign positive will be randomized to receive either the active study medication, rFVIIa, at 80 mcgkg, or to receive a placebo an inactive substance. Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth determined to be CTA spot sign negative will be enrolled into a prospective observational group. 